Saturday 17 October 2026 Export GPCR’s income statement to Excel — free account

Structure Therapeutics Inc. Sponsored ADR

In the quarter to June 2026, EPS fell 36.4% and free cash flow fell 119.2%, each against the same quarter a year earlier.

20.95 1.24 −5.59%

Follow GPCR

Alert me

Market cap: $1.6B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 4.39%

Capital & Financial Ratios $m

Market Cap 1,580.00

Revenue —

Net Income (214.83)

Free Cash Flow (224.50)

Net Debt (1,342.66)

Current Ratio 20.75

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 1.12

Past 5Y EPS Growth —

This Y EPS Growth (108.19%)

Next Y EPS Growth (28.83%)

Next Y revenue growth —

Next 5Y EPS Growth (25.71%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 0.90%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	467	884	1,446	1,343
Receivables	—	—	100	—
Inventory	—	—	—	—
Other	—	—	—	—
	474	891	1,570	1,372

	2023	2024	2025	Q'26
Payables	5	8	14	11
ST’ Debt	—	—	—	—
Other	—	—	—	—
	25	36	63	66

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	111.85%	161.46%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	15	(120)	—	—	—
’25	(52)	(55)	(51)	(64)	(222)
’24	(34)	(26)	(20)	(36)	(117)
’23	(20)	(17)	(21)	(22)	(79)
’22	(14)	(10)	(10)	(12)	(46)
’21	—	—	—	(32)	(32)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	14	(120)	—	—	—
’25	(53)	(55)	(53)	(66)	(226)
’24	(34)	(27)	(20)	(36)	(118)
’23	(20)	(17)	(21)	(23)	(82)
’22	(14)	(10)	(11)	(12)	(46)
’21	—	—	—	(33)	(33)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.05)	(1.46)	—	—	—
’25	(0.82)	(1.07)	(1.12)	0.63	(2.39)
’24	(0.56)	(0.53)	(0.59)	(0.65)	(2.33)
’23	(0.75)	(0.61)	(0.62)	(0.17)	(2.44)
’22	(4.33)	(4.43)	(3.81)	(3.49)	(16.06)
’21	—	—	—	—	(14.02)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	—	20.80	25.90	13.22	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	—	75.02	62.74	94.90
People
People	Employees	—	—	—	—	—	68	68	93	163	220
	Revenue/emp, $m	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	—	0.00	0.00	0.00	—	—	—
	EBT	—	—	—	—	(16)	(38)	(51)	(89)	(122)	(141)
	EBT margin, %	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	—	—	—	(16)	(38)	(51)	(90)	(123)	(141)
	Depreciation	—	—	—	—	0	0	(1)	0	1	2
Per share, $
Per share, $	Revenue	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	—	—	(0.44)	(14.02)	(16.06)	(2.44)	(2.33)	(2.39)
	Cash flow	—	—	—	—	(0.39)	(11.85)	(14.44)	(2.16)	(2.22)	(3.75)
	Capex	—	—	—	—	0.00	(0.44)	(0.05)	(0.06)	(0.02)	(0.06)
	Free cash flow	—	—	—	—	(0.39)	(12.29)	(14.48)	(2.22)	(2.24)	(3.81)
	Book value	—	—	—	—	0.97	37.67	26.55	12.33	16.43	25.61
	Shares, m	—	—	—	—	37	3	3	37	53	59
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	(14)	(32)	(46)	(79)	(117)	(222)
	Capex	—	—	—	—	0	(1)	0	(2)	(1)	(4)
	Free cash flow	—	—	—	—	(14)	(33)	(46)	(82)	(118)	(226)
Balance, $m
Balance, $m	Working capital	—	—	—	—	35	101	80	449	855	1,507
	Total debt	—	—	—	—	0	1	0	—	—	—
	Net debt	—	—	—	—	(37)	(107)	(91)	(467)	(884)	(1,446)
	Shareholders’ equity	—	—	—	—	36	102	85	453	865	1,516
Returns, %
Returns, %	ROA	—	—	—	—	0.00	(58.41)	(50.56)	(30.91)	(17.69)	(11.35)
	ROIC	—	—	—	—	0.00	0.00	0.00	0.00	0.00	(157.24)
	ROE	—	—	—	—	0.00	100.37	58.75	(53.06)	(18.60)	(11.86)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
OCUL Ocular Therapeutix, Inc.	$1.6B	— (loss-making)	— (loss-making)	+0.12% (above 0%: growing)	n/m	−25.35% (below 0%: shrinking)	85.08%	(609.34%)	Compare
NTLA Intellia Therapeutics, Inc.	$1.6B	— (loss-making)	— (loss-making)	−46.23% (below 0%: shrinking)	n/m	+15.05% (above 0%: growing)	100.00%	(1,472.25%)	Compare
STOK Stoke Therapeutics, Inc.	$1.6B	— (loss-making)	— (loss-making)	−32.51% (below 0%: shrinking)	n/m	−128.97% (below 0%: shrinking)	100.00%	(701.65%)	Compare
GPCR Structure Therapeutics Inc. Sponsored ADR	$1.6B	— (loss-making)	—	—	n/m	−119.15% (below 0%: shrinking)	0.00%	0.00%
QURE uniQure N.V.	$1.6B	— (loss-making)	— (loss-making)	+11.00% (above 0%: growing)	n/m	+27.66% (above 0%: growing)	94.01%	(893.73%)	Compare
KRSA Korsana Biosciences, Inc.	$1.5B	— (loss-making)	— (loss-making)	−43.24% (below 0%: shrinking)	n/m	−184.69% (below 0%: shrinking)	100.00%	0.00%	Compare
MAZE Maze Therapeutics, Inc.	$1.5B	— (loss-making)	—	—	n/m	+50.21% (above 0%: growing)	100.00%	0.00%	Compare
ABSI Absci Corporation	$1.5B	— (loss-making)	— (loss-making)	−46.37% (below 0%: shrinking)	n/m	−71.74% (below 0%: shrinking)	100.00%	(10,741.51%)	Compare
IMCR Immunocore Holdings PLC Sponsored ADR	$1.5B	— (loss-making)	208×	+18.34% (above 0%: growing)	n/m	−40.74% (below 0%: shrinking)	99.06%	(2.58%)	Compare
Median of peers	$1.5B	—	—	−32.51%	—	−33.04%	100.00%	(655.49%)

All 614 Biotechnology stocks →

Structure Therapeutics Inc. Sponsored ADR (GPCR) key facts

Structure Therapeutics Inc. Sponsored ADR (GPCR) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, GPCR traded at $20.95, a market capitalization of $1.6 billion.
Return on equity was −11.9% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.